Molecular imaging utilising prostate-specific membrane antigen (PSMA) as a target has increasingly been mentioned at key conferences and meetings. PSMA is a membrane metalloenzyme that is overexpressed in prostate cancer, with the degree of expression appears to correlate with tumour aggression. The commercially available ProstaScint scan utilises the radiolabelled monoclonal antibody indium-111-capromab pendetide as the molecular imaging agent for PSMA. This review article gives a comprehensive assessment of the current literature focusing on the clinical value of this mode of imaging. Early data is from largely small and / or retrospective studies and the most important evidence that has been identified thus far is in biochemical recurrence in prostate cancer. The review highlights the need for prospective trials to validate the technique but recognises that this is a new and exciting area which may improve the management of prostate cancer patients in the future.